The launch of a €500 million sale process for Indiba underscores growing private‑equity interest in medical‑aesthetic technology
Executive summary: Charme and Miura have initiated a sale process for Indiba, engaging Evercore as advisor, with an expected valuation of about €500 million. The transaction highlights strong fund appetite for niche medical‑aesthetic assets and could set a pricing benchmark for similar deals.
Who is involved: Charme, Miura, Evercore (advisor), and various private‑equity funds expressing interest.
Likely next: Evercore will solicit binding offers, and a closing is anticipated once bids are received, though no specific dates were provided.
Charme and Miura have formally kicked off a sale process for Indiba, the Spanish manufacturer of radio‑frequency aesthetic devices, mandating Evercore to run the auction with a price tag of roughly €500 million. The move comes as several private‑equity firms have already signaled interest, highlighting a broader appetite among financial sponsors for niche medical‑technology assets that benefit from rising demand for non‑invasive cosmetic procedures. Indiba’s focus on professional‑grade equipment for skin tightening and body contouring positions it in a segment that has shown resilient growth even during economic downturns, making it an attractive target for funds seeking exposure to recurring revenue streams from consumables and service contracts. The €500 million valuation implies a multiple that reflects both the company’s established distribution network across Europe and Latin America and the scalability of its technology platform. While no financial details or timetable have been disclosed, the involvement of a top‑tier adviser and early interest from multiple bidders suggest a competitive process that could conclude within the next few quarters. The outcome will serve as a barometer for how private equity values specialized aesthetic‑tech businesses amid increasing consolidation in the broader medtech landscape.
Timeline
- — Charme y Miura lanzan el proceso de venta de Indiba valorada en 500 millones (Expansión)
Analysis — what this means
Sectors affected
- Medical aesthetic device manufacturing
- Radiofrequency‑based skin treatment sector
Key entities
Sources
Open the full interactive case file on Beyond →